NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî äåòñêîé äåðìàòîëîãèè â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Baroni A, Buommino E, De Gregorio V, et al: Structure and function of the epidermis related to barrier properties, Clin Dermatol 30(3):257–262, 2012.
Hashmi S, Marinkovich MP: Molecular organization of the basement membrane zone, Clin Dermatol 29(4):398–411, 2011.
Schneider MR, Schmidt-Ullrich R, Paus R: The hair follicle as a dynamic miniorgan, Curr Biol 19(3):R132-R142, 2009.
Cheng W, Gilliam AC, Castrovinci A, Pazirandeh M: Anti-thyroid autoantibody- associated interface dermatitis in individuals with undifferentiated connective tissue disease — an unrecognized subset of autoimmune disease? J Rheumatol 34:81–88, 2006.
Chung WH, Wang CW, Dao RL: Severe cutaneous adverse drug reactions, J Dermatol 43:758–766, 2016.
Darlenski R, Kazandjieva J, Tsankov N: Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, Clin Dermatol 33:538–541, 2015.
Fawcett RS, Linford S, Stulberg DL: Nail abnormalities: clues to systemic disease, Am Fam Physician 69:1417–1424, 2004.
Feichtinger RG, Sperl W, Bauer JW, Kofler B: Mitochondrial dysfunction: a neglected component of skin diseases, Exp Dermatol 23:607–614, 2014.
Hymes SR, Alousi AM, Cowen EW: Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease, J Am Acad Dermatol 66(4): 515.e1-515.e18, 2012.
Hymes SR, Alousi AM, Cowen EW: Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease, J Am Acad Dermatol 66(4):535.e1-535.e16, 2012.
Kano Y, Ishida T, Hirahara K, Shiohara T: Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome, Med Clin North Am 94:743–759, 2010.
Kurklinsky AK, Miller VM, Rooke TW: Acrocyanosis: the flying Dutchman, Vasc Med 16(4):288–301, 2011.
Kurtzman DJ, Jones T, Lian F, Peng LS: Metastatic Crohn's disease: a review and approach to therapy, J Am Acad Dermatol 71:804–813, 2014.
Misery L, Bodere C, Genestet S, et al: Small-fibre neuropathies and skin: news and perspectives for dermatologists, Eur J Detmatol 24(2):147–153, 2014.
Patel LM, Lambert PJ, Gagna CE, et al: Cutaneous signs of systemic disease, Clin Dermatol 29:511–522, 2011.
Pope E, Laxer RM: Diagnosis and management of morphea and lichen sclerosus and atrophicus in children, Pediatr Clin North Am 61(2):309–319, 2016.
Thakral A, Klein-Gitelman MS: An update on treatment and management of pediatric systemic lupus erythematosus, Rheumatol Ther 3(2):209–219, 2016.
Webb K, Hlela C, Jordaan HF, et al: A review and proposed approach to the neutrophilic dermatoses of childhood, Pediatr Dermatol 32:437–446, 2015.
Ye YM, Thong BYH, Park HS: Hypersensitivity to antiepileptic drugs, Immunol Allergy Clin North Am 34:633–643, 2014.
Dabade TS, Davis DMR, Wetter DA, et al: Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: Experience with 218 patients over 30 years at Mayo Clinic, J Am Acad Dermatol 67(1):100–106, 2012.
Quatrano NA, Dinulos JG: Current principles of sunscreen use in children, Curr Opin Pediatr 25:122–129, 2013.
Siegfried EC, Jaworski JC, Hebert AA: Topical calcineurin inhibiotrs and lymphoma risk: evidence update with implications for daily practice, Am J Clin Dermatol 14:163–178, 2013.
Wollenberg A, Oranje A, Deleuran M, et al: European Task Force on Atopic Dermatitis / EADV Eczema Task Force. ETFAD/EADV Eczema task force 2015 position paper on the diagnosis and treatment of atopic dermatitis in adult and pediatric patients, J Eur Acad Dermatol Venereol 30(5):729–747, 2016.
Ghosh S: Neonatal pustular dermatosis: an overview, Indian J Dermatol 60:211, 2015.
Hackbart BA, Arita JH, Pinho RS, et al: Mongolian spots are not always a benign sign, J Pediatr 162:1070, 2013.
Hernondez-Martm A, Nuno-Gonzalez A, Colmenero I, et al: Eosinophilic pustular folliculitis of infancy: a series of 15 cases and review of the literature, J Am Acad Dermatol 68:150–155, 2013.
Mimouni-Bloch A, Finezilber Y, Rothschild M, Raas-Rothschild A: Extensive Mongolian spots and lysosomal storage diseases, J Pediatr 170:333, 2016.
Miquel J, Piyaraly S, Dupuy A, et al: Congenital cases of concomitant Harlequin and Horner syndromes, J Pediatr 182:389–392, 2017.
Reginatto FP, DeVilla D, Muller FM, et al: Prevalence and characterization of neonatal skin disorders in the first 72h of life, J Pediatr (Rio J) S0021-7557:2016. 30276-5.
Valerio E, Barlotta A, Lorenzon E, et al: Harlequin color change: neonatal case series and brief literature review, AJP Rep 5:73–76, 2015.
Chien MM, Chen KL, Chiu HC: The «hair collar» sign, J Pediatr 168:246, 2016.
Fernondez Garda MS, Teruya-Feldstein J: The diagnosis and treatment of dyskeratosis congenita: a review, J Blood Med 5:157–167, 2014.
McGovern M, Mulligan S, Carney O, et al: Ultrasound investigation of sacral dimples and other stigmata of spinal dysraphism, Arch Dis Child 98(10):784–786, 2013.
Sarikaya Solak S, Kivanc Altunay I, Tukenmez Demirci G, et al: Prevalence of congenital cutaneous anomalies in 1000 newborns and a review of the literature, Am J Perinatol 33(1):79–83, 2016.
Turkyilmaz Z, Karabulut R, Bayazit YA, et al: Congenital neck masses in children and their embryologic and clinical features, B-ENT 4:7–18, 2008.
Valerio E, Fantinato M, Giovannini I, Cutrone M: Aplasia cutic congenital with «vanishing twin», J Pediatr 166:1316, 2015.
Wang L, Jin X, Zhao X, et al: Focal dermal hypoplasia: updates, Oral Dis 20(1):17–24, 2014.
Xunhong D, Yang G, Yu D, et al: Aplasia cutis congenita: a case report and literature review, Exp Ther Med 10(5):1893–1895, 2015.
Alhashem AM, Majeed-Saiden MA, Ammari AN, et al: Crispon/ClSS1 syndrome: a case series, Am J Med Genet A 170A:1236–1241, 2016.
Chen YC, Wu CS, Chen GS, et al: Identification of subgroups of acquired idiopathic generalized anhidrosis, Neurologist 14(5):318–320, 2008.
Cluzeau C, Hadj-Rabia S, Jambou M, et al: Only four genes (EDA1, EDAR, EDARADD, and WNT10A) account for 90% of hypohidrotic/anhidrotic ectodermal dysplasia cases, Hum Mutat 32(1):70–72, 2011.
Der Kaloustian VM: Hidrotic ectodermal dysplasia 2. In Pagon RA, Adam MP, Ardinger HH, et al, editors: GeneReviews®, Seattle (WA), 1993–2017, University of Washington, Seattle. 25 April 2005 [updated 22 January 2015].
Fete M, Hermann J, Behrens J, Huttner KM: X-Linked hypohydrotic ectodermal dysplasia (XLHED): clinical and diagnostic insights from an international patient registry, Am J Med Genet A 164A:2437–2442, 2014.
Gunadi MK, Ohta M, et al: Two novel mutations in the ED1 gene in Japanese families with X-linked hypohidrotic ectodermal dysplasia, Pediatr Res 65:453–457, 2009.
Trzeciak WH, Koczorowski R: Molecular basis of hypohidrotic ectodermal dysplasia: an update, J Appl Genet 57:51–61, 2016.
Wataya-Kaneda M: Genetic disorders with dyshidrosis: ectodermal dysplasia, incontinentia pigmenti, Fabry disease, and congenital insensitivity to pain with anhidrosis, Curr Probl Dermatol 51:42–49, 2016.
Wright JT, Grange DK, Richter MK: Hypohidrotic ectodermal dysplasia. In Pagon RA, Adam MP, Ardinger HH, et al, editors: GeneReviews®, Seattle (WA), 1993–2017, University of Washington, Seattle. 28 April 2003 [updated 15 May 2014].
Chan H, McKay C, Adams S, et al: RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds, Pediatrics 131(6):e1739-e1747, 2013.
Chacan RP, del Boz Gonzalez J, Moran JN: Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report, Pediatrics 135(4):e1064-e1066, 2015.
Dompmartin A, Vikkula M, Boon LM: Venous malformation: update on aetiopatho- genesis, diagnosis and management, Phlebology 25(5):224–235, 2010.
Drolet BA, Frommelt PC, Chamlin SL, et al: Initiation and use of propranolol for infantile hemangioma: report of a consensus conference, Pediatrics 131(1):128–140, 2013.
Drolet BA, Trenor CC 3rd, Brandao LR, et al: Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma, J Pediatr 163(1):285–291, 2013.
Garzon MC, Epstein LG, Heyer GL, et al: PHACE syndrome: consensus-derived diagnosis and care recommendations, J Pediatr 178:24–33, 2016.
Glick ZR, Frieden IJ, Garzon MC: Diffuse neonatal hemangiomatosis: an evidence-based review of case reports in the literature, J Am Acad Dermatol 67(5):898–903, 2012.
Happle R: Capillary malformations: a classification using specific names for specific skin disorders, J Eur Acad Dermatol Venereol 29:2295–2305, 2015.
Holland KE, Drolet BA: Approach to the patient with an infantile hemangioma, Dermatol Clin 31(2):289–301, 2013.
Kim KH, Choi TH, Choi Y, et al: Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma — a randomized clinical trial, JAMA Dermatol 155(6):529–536, 2017.
Loaute-Labr?ze C, Boccara O, Degrugillier-Chopinet C, et al: Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review, Pediatrics 138(4):e20160353, 2016.
Lou Y, Peng WJ, Cao Y, et al: The effectiveness of propranolol in treating infantile hemangiomas: a meta-analysis including 35 studies, Br J Clin Pharmacol 78:44–57, 2014.
The Medical Letter: Oral propranolol (Hemangeol) for infantile hemangioma, Med Lett Drugs Ther 56:61–62, 2014.
Nahm WK, Moise S, Eichenfield LF, et al: Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation, J Am Acad Dermatol 50(5): S101-S106, 2004.
Patrick LM, Oh C, Bauman N, et al: Rapid involuting congenital hemangioma in the setting of PHACE association, Pediatrics 133:e1777-e1780, 2014.
Pottgen K, Lucky A, Adams D, et al: Topical timolol maleate treatment of infantile hemangiomas, Pediatrics 138(3):e20160255, 2016.
Shah SD, Baselga E, McCuaig C, et al: Rebound growth of infantile hemangiomas after propranolol therapy, Pediatrics 137(4):e20151754, 2016.
Wassef M, Blei F, Adams D, et al: Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies, Pediatrics 136(1):e203-e214, 2015.
Cordoro KM, Gupta D, Frieden IJ, et al: Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children, J Am Acad Dermatol 68(6):913–925, 2013.
Dika E, Ravaioli GM, et al: (2017), Spitz Nevi and Other Spitzoid Neoplasms in Children: Overview of Incidence Data and Diagnostic Criteria, Pediatr Dermatol 34:25–32, 2017.
Gupta M, Berk DR, Gray C, et al: Morphologic features and natural history of scalp nevi in children, Arch Dermatol 146(5):506–511, 2010.
Inoue M, Fukuda M, Ishii E, Sayama K: Linear leukoplakia and central nervous system lesions: a clinical clue to the diagnosis of hypomelanosis of ito, J Pediatr 167:771, 2015.
Kinsler VA, Thomas AC, Ishida M, et al: Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS, J Invest Dermatol 133(9):2229–2236, 2013.
LaChance A, Shahriari M, Kerr PE, Grant-Kels JM: Melanoma: Kids are not just little people, Clin Dermatol 34(6):747–748, 2016.
Price HN: Congenital melanocytic nevi: update in genetics and management, Curr Opin Pediatr 28:476–482, 2016.
Reed D, Kudchadkar R, Zager JS, et al: Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults, J Natl Compr Canc Netw 11(6):679–686, 2013.
Schaffer J: Update on melanocytic nevi in children, Clin Dermatol 33(3):368–386, 2015.
Vourch-Jourdain M, Martin L, Barbarot S, et al: Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review, J Am Acad Dermatol 68(3):493–498, 2013.
Kresak JL, Walsh M: Neurofibromatosis: a review of NF1, NF2, and schwannomatosis, J Pediatr Genet 5:98–104, 2016.
Shah KN: The diagnostic and clinical significance of cafe-au-lait macules, Pediatr Clin North Am 57(5):1131–1153, 2010.
Stratakis E: Hereditary syndromes predisposing to endocrine tumors and their skin manifestations, Rev Endocr Metab Disord 17:381–388, 2016.
Warner C, Dinulos JG: Core concepts in congenital melanocytic nevi and infantile hemangiomas, Curr Opin Pediatr 26:130–135, 2014.
Zacharin M: The spectrum of McCune Albright syndrome, Pediatr Endocrinol Rev 412–418, 2007.
De Menezes A, Oliveira de Carvalho F, Barreto R, et al: Pharmacologic treatment of vitiligo in children and adolescents: a systematic review, Pediatr Dermatol 34(1):13–24, 2017.
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N: Vitilgo, Lancet 386:74–82, 2015.
Ezzedine K, Silverberg N: A practical approach to the diagnosis and treatment of vitiligo in children, Pediatrics 138(1):e2015126, 2016.
Ezzedine K, Whitton M, Pinart M: Interventions for vitiligo, JAMA 316(16):1708–1709, 2016.
Gill L, Zarbo A, Isedeh P, et al: Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study, J Am Acad Dermatol 74(2):295–302, 2016.
Kaplan J, De Domenico I, Ward DM: Chediak-Higashi syndrome, Curr Opin Hematol 15:22–29, 2008.
Karaman A, Aliagaoglu C: Waardenburg syndrome type 1, Dermatol Online J 30:21, 2006. LePoole IC, Luiten RM: Autoimmune etiology of generalized vitiligo, Curr Dir Autoimmun 10:237–243, 2008.
Que S, Weston G, Suchecki J, Ricketts J: Pigmentary disorders of the eyes and skin, Clin Dermatol 33:147–158, 2015.
Rork JF, Rashighi M, Harris JE: Understanding autoimmunity of vitiligo and alopecia areata, Curr Opin Pediatr 28:463–469, 2016.
Seward SL Jr, Gahl WA: Hermansky-Pudlak syndrome: health care throughout life, Pediatrics 132(1):153–160, 2013.
Taseb A, Picardo M: Vitiligo, N Engl J Med 360:160–168, 2009.
Wei A, He X, Li W: Hypopigmentation in Hermansky-Pudlak syndrome, J Dermatol 40:325–329, 2013.
Federal Drug Administration: FDA warns of rare acetaminophen risk, August 2013. Available at: http://www.fda.gov/forconsumers/consumerupdates/ucm363010.htm.
Gober MD, Laing JM, Burnett JW, et al: The herpes simplex virus gene Pol expressed in herpes-associated erythema multiforme lesions upregulates/activates SP1 and inflammatory cytokines, Dermatology 215:97–106, 2007.
Moreau JF, Watson RS, Hartman ME, et al: Epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in hospitalized children in the United States, Pediatr Dermatol 31(2):163–168, 2014.
Schalock PC, Dinulos JG, Pace N, et al: Erythema multiforme due to Mycoplasma pneumoniae infection in two children, Pediatr Dermatol 23(6):546–555, 2006.
Schneider G, Kachroo S, Jones N, et al: A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens-Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data, Pharmacoepidemiol Drug Saf 21(Suppl 1):236–239, 2012.
Siedner-Weintraub Y, Gross I, Almog D, et al: Paediatric erythema multiforme: epidemiological, clinical, and laboratory characteristics, Acta Derm Venereol 2016. doi:10.2340/00015555-2569.
Sokumbi O, Wetter DA: Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist, Int J Dermatol 51:889–902, 2012.
Tatnall FM, Schofield JK, Leigh IM: A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme, Br J Dermatol 132:267–270, 1995.
Wetter DA, Davis MDP: Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at the Mayo Clinic, 2000 to 2007, J Am Acad Dermatol 62:45–53, 2010.
Atkinson TP, Boppana S, Theos A, et al: Stevens-Johnson syndrome in a boy with macrolide-resistant Mycoplasma pneumoniae pneumonia, Pediatrics 127:e1605-e1609, 2011.
Barron S, Del Vecchio M, Aronoff S: Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies, Int J Dermatol 54:108–115, 2015.
Cavalcante EG, Guissa VR, Jesus AA, et al: Stevens-Johnson syndrome in a juvenile systemic lupus erythematosus patient, Lupus 20:1439–1441, 2011.
Chung WH, Chang WC, Lee YS, et al: Genetic variants associated with phenytoin-related severe cutaneous adverse reactions, JAMA 312:525–534, 2014.
Chung WH, Hung SI, Yang JY, et al: Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nat Med 14:1343–1350, 2008.
Ciralsky JB, Sippel KC, Gregory DG: Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis, Curr Opin Pediatr 24:321–328, 2013.
de Prost N, Ingen-Housz-Oro S, Duong T, et al: Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis, Medicine (Baltimore) 89(1):28–36, 2010.
Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, et al: A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children, J Popul Ther Clin Pharmacol 18:e121-e133, 2011.
Ferrel PB, McLeod HL: Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations, Pharma-cogenomics 9:1543–1546, 2008.
Finkelstein Y, Soon GS, Acuna P, et al: Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children, Pediatrics 128:723–728, 2011.
Huang YC, Li YC, Chen TJ: The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis, Br J Dermatol 167(2):424–432, 2012.
Kaniwa N, Saito Y, Aihara M, et al: HLA-B locus in Japanese patients with anti-epileptic and allopurinol related Stevens-Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics 9:1617–1622, 2008.
Kohanim S, Palioura S, Saeed HN, et al: Stevens-Johnson syndrome / toxic epidermal necrolysis — a comprehensive review and guide to therapy I. Systemic disease, Ocul Surf 14(1):2–19, 2016.
Kohanim S, Palioura S, Saeed HN, et al: Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome / toxic epidermal necrolysis — a comprehensive review and guide to therapy II. Ophthalmic disease, Ocul Surf 14(2):168–188, 2016.
Levi N, Bastuji-Garin S, Mockenhaupt M, et al: Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis, Pediatrics 123:e297-e304, 2009.
Okubo Y, Nochioka K, Testa M, Chan T: Nationwide survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in children in the United States, Pediatr Dermatol 1–3, 2016.
Olson D, Watkins LKF, Demirjian A, et al: Outbreak of Mycoplasma pneumoniae-associated Stevens-Johnson syndrome, Pediatrics 136(2):e386-e394, 2015.
Prindaville B, Newell B, Nopper A, Horii K: Mycoplasma pneumonia-associated mucocutaneous disease in children: dilemmas in classification, Pediatr Dermatol 31:670–675, 2014.
Rock N, Belli D, Bajwa N: Erythema bullous multiforme: a complication of mycoplasma pneumonia infection, J Pediatr 164:421, 2014.
Sauteue PMM, Gansser-Kalin U, Lautenschlager S, et al: Fuchs syndrome associated with mycoplasma pneumonia (Stevens-Johnson syndrome without skin lesions), Pediatr Dermatol 28:474–476, 2011.
Schalock PC, Thyssen JP, Dinulos JG: Mycoplasma pneumoniae-associated mucositis: by any other name is not so sweet, Pediatr Dermatol 29(3):392, 2012.
Slentz DH, Hemmati HD: Management of Stevens-Johnson syndrome and toxic epidermal necrolysis, EyeNet Magazine 37–39, 2013.
Sotozono C, Ueta M, Koizumi N, et al: Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications, Ophthalmology 116:685–690, 2009.
Thomas L, Weng M, Schulze R Jr, et al: Ophthalmic considerations in Stevens-Johnson syndrome, J Pediatr 175:235, 2016.
Tseng SCG: Acute management of Stevens-Johnson syndrome and toxic epidermal necrolysis to minimize ocular sequelae, Am J Ophthalmol 147(6):949–951, 2009.
Van Batavia JP, Chu DI, Long CJ, et al: Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis, J Pediatr Urol 2017. doi:10.1016/j.jpurol.2017.01.018.
Barron S, Del Vecchio M, Aronoff S: Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies, Int J Dermatol 54:108–115, 2015.
Bastuji-Garin S, Rzany B, Stern RS: Clinical classification of cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme, Arch Dermatol 129:92–96, 1993.
Bellodi-Schmidt F, Shah K: Beyond psoriasis: novel uses for biologic response modifiers in pediatric dermatology, Pediatr Dermatol 33:18–27, 2016.
Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, et al: A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children, J Popul Ther Clin Pharmacol 18:e121-e133, 2011.
Endorf FW, Cancio LC, Gibran NS: Toxic epidermal necrolysis: clinical guidelines, J Burn Care Res 29:706–712, 2008.
Huang YC, Li YC, Chen TJ: The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis, Br J Dermatol 167(2):424–432, 2012.
Konda S, Fernandez AP, Berman B, et al: Toxic epidermal necrolysis in the setting of systemic lupus erythematous, Int J Dermatol 50:1270–1275, 2011.
Levi N, Bastuji-Garin S, Mockenhaupt M, et al: Medications as risk factors of Stevens- Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis, Pediatrics 123:e297-e304, 2009.
Schwartz RA, McDonough PH, Lee BW: Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis, J Am Acad Dermatol 69(2):173.e1-173.e13, 2013.
Schwartz RA, McDonough PH, Lee BW: Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, prevention, and treatment, J Am Acad Dermatol 69(2): 187.e1-187.e16, 2013.
Valeyrie-Allanore L, Bastuji-Garin S, Guegan S, et al: Prognostic value of histologic features of toxic epidermal necrolysis, J Am Acad Dermatol 68(2):e29-e35, 2013.
White JC, Appleman S: Infliximab/plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis, Pediatrics 134:e1194-e1198, 2014.
Abrams ML, Smidt A, Benjamin L, et al: Congenital epidermolysis bullosa acquisita, Arch Dermatol 147:337–341, 2011.
Cohn HI, Teng JMC: Advancement in management of epidermolysis bullosa, Curr Opin Pediatr 28:507–516, 2016.
Fine JD, Bruckner-Tuderman L, Eady RA, et al: Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification, J Am Acad Dermatol 70(6):1103–1126, 2014.
Fine JD, Mellerio JE: Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues, J Am Acad Dermatol 61(3):367–384, 2009.
Fine JD, Mellerio JE: Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs, J Am Acad Dermatol 61(3):387–402, 2009.
Geyer MB, Radhakrishnan K, Giller R, et al: Reduced toxicity conditioning and allogeneic hematopoietic progenitor cell transplantation for recessive dystrophic epidermolysis bullosa, J Pediatr 167:765–769, 2015.
Has C, Sparta G, Kiritsi D, et al: Integrin a3 mutations with kidney, lung, and skin disease, N Engl J Med 366:1508–1514, 2012.
Ida JB, Azizkhan RG, Lucky AW, et al: Upper airway complications of junctional epidermolysis bullosa, J Pediatr 160:657–661, 2012.
Lai-Cheong JE, McGrath JA: Kindler syndrome, Dermatol Clin 28(1):119–124, 2010.
Siprashvili Z, Nguyen NT, Gorell ES, et al: Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa, JAMA 316(17):1808–1817, 2016.
Tolar J, Wagner JE: Allogenic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix, Lancet 382:1214–1222, 2013.
Uitto J, Bruckner-Tuderman L, Christiano AM, et al: Progress toward treatment and cure of epidermolysis bullosa: summary of the DEBRA international research symposium EB2015, J Invest Dermatol 136:352–358, 2016.
Wagner JE, Ishida-Yamamoto A, McGrath JA, et al: Bone marrow transplantation for recessive dystrophic epidermolysis bullosa, N Engl J Med 363(7):629–638, 2010.
Webber B, Tolar J: From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa, Mol Ther 23:987–992, 2015.
Amagai M, Ikeda S, Shimizu H, et al: A randomized double-blind trial of intravenous immunoglobulin for pemphigus, J Am Acad Dermatol 60:595–603, 2009.
Ayla-Cortes AS, Martinez-Cabriales SA, Welsh O, et al: Childhood bullous pemphigold: a treatment challenge, J Pediatr 179:271, 2016.
Baratta A, Camarillo D, Papa C, et al: Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF), Pediatr Dermatol 30:240–244, 2013.
Bellodi-Schmidt F, Shah K: Beyond psoriasis: novel uses for biologic response modifiers in pediatric dermatology, Pediatr Dermatol 33:18–27, 2016.
Fuertes I, Guilabert A, Mascaro JM, et al: Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature, Dermatology 221(1):13–16, 2010.
Fuertes I, Luelmo J, Leal L, et al: Refractory childhood pemphigoid successfully treated with rituximab, Pediatr Dermatol 30(5):e96-e97, 2013.
Grantham HJ, Stocken DD, Reynolds NJ: Doxycycline: a first-time treatment for bullous pemphigoid?, Lancet 389:1586–1588, 2017.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al: First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicenter, parallel-group, open-label randomized trial, Lancet 389:2031–2040, 2017.
Joly P, Mouquet H, Roujeau JC, et al: A single cycle of rituximab for the treatment of severe pemphigus, N Engl J Med 357:545–552, 2009.
Marathe K, Lu J, Morel K: Bullous diseases: kids are not just little people, Clin Dermatol 33:644–656, 2015.
Qian Y, Jeong JS, Maldonado M, et al: Cutting edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen, J Immunol 189:1535–1539, 2012.
Razzaque Ahmed A, Spigelman Z, Cavacini LA, et al: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin, N Engl J Med 355:1772–1778, 2006.
Schmidt E, Zillikens D: Pemphigoid diseases, Lancet 381:320–332, 2013.
Alonso-Llamazares J, Gibson LE, Rogers RS: Clinical, pathologic and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience, Int J Dermatol 46:910–919, 2007.
Marathe K, Lu J, Morel K: Bullous diseases: kids are not just little people, Clin Dermatol 33:644–656, 2015.
Templet JT, Welsh JP, Cusack CA: Childhood dermatitis herpetiformis: a case report and review of the literature, Cutis 80:473–476, 2007.
Zone JJ: Skin manifestations of celiac disease, Gastroenterology 128:S87-S91, 2005.
Fortuna G, Marinkovich MP: Linear immunoglobulin A bullous dermatosis, Clin Dermatol 30(1):38–50, 2012.
Ho JC, Ng PL, Tan SH, et al: Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid, Pediatr Dermatol 24:e40-e43, 2007.
Johnson EF, Jacobs MH, Smidt AC: Annular vesiculobullous eruption in a healthy young man, JAMA 310:2559, 2013.
Kong Y, Lim Y, Chandran N: Retrospective study on autoimmune blistering diseases in paediatric patients, Pediatr Dermatol 32:845–852, 2015.
Marathe K, Lu J, Morel K: Bullous diseases: kids are not just little people, Clin Dermatol 33:644–656, 2015.
Nanda A, Dvorak R, Al-Sabah H, et al: Linear IgA disease of childhood: an experience from Kuwait, Pediatr Dermatol 23:443–447, 2006.
Onodera H, Mohm MC Jr, Yoshinda A, et al: Drug-induced linear IgA bullous dermatosis, J Dermatol 32:759–764, 2005.
Fonacier LS, Aquino MR, Mucci T: Current strategies in treating severe contact dermatitis in pediatric patients, Curr Allergy Asthma Rep 12(6):599–606, 2012.
Goldenberg A, Admani S, Pelletier JL, Jacob SE: Belt buckles — increasing awareness of nickel exposure in children: a case report, Pediatrics 136(3):e691-e693, 2015.
Goldenberg A, Silverberg N, Silverberg JI, et al: Pediatric Allergic Contact Dermatitis: Lessons for Better Care, J Allergy Clin Immunol Pract. 3(5):661–667, 2015.
Shin HT: Diagnosis and management of diaper dermatitis, Pediatr Clin North Am 61:367–382, 2014.
Pugliarello S, Cozzi A, Gisondi P, et al: Phenotypes of atopic dermatitis, J Dtsch Dermatol Ges 9(1):12–20, 2011.
Miazek N, Michalek I, Pawlowska-Kisiel M, et al: Pityriasis Alba-Common Disease, Enigmatic Entity: Up-to-Date Review of the Literature, Pediatr Dermatol 32:786–791, 2015.
Wollina U: Pompholyx: a review of clinical features, differential diagnosis, and management, Am J Clin Dermatol 11(5):305–314, 2010.
Dessinioti C, Katsambas A: Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies, Clin Dermatol 31(4):343–351, 2013.
Chantorn R, Lim HW, Shwayder TA: Photosensitivity disorders in children: part I, J Am Acad Dermatol 67:1093.e1-1093.e18, 2012.
Di Silva B, Banney L, Uttley W, et al: Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis, Pediatr Dermatol 17(6):480–483, 2000.
Ferrari A, Bisogno G, Cecchetto G, et al: Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience, J Pediatr 164:375–382, 2014.
Giordano CN, Yew YW, Spivak G, Lim HW: Understanding photodermatoses associated with defective DNA repair: Syndromes with cancer predisposition, J Am Acad Dermatol 75(5):855–870, 2016.
Giordano CN, Yew YW, Spivak G, Lim HW: Understanding photodermatoses associated with defective DNA repair: Photosensitive syndromes without associated cancer predisposition, J Am Acad Dermatol 75(5):873–882, 2016.
Kutlubay Z, Sevim A, Engin B, Tuzun Y: Photodermatoses, including phototoxic and photoallergic reactions (internal and external), Clin Dermatol 32(1):73–79, 2014.
Lane AM, McKay JT, Bonkovsky HL: Advances in the management of erythropoietic protoporphyria — role f afemelanotide, Appl Clin Genet 9:179–189, 2016.
Millard TP, Hawk JLM: Photosensitivity disorders — cause, effect and management, Am J Clin Dermatol 3(4):239–246, 2002.
Mowad CM, Anderson B, Scheinman P, et al: Allergic contact dermatitis: Patient management and education, J Am Acad Dermatol 74(6):1043–1054, 2016.
Moyer VA, US Preventive Services Task Force: Behavioral counseling to prevent skin cancer: US Preventive Services Task Force recommendation statement, Ann Intern Med 157:1–8, 2012.
Policy Statement American Academy of Pediatrics, Council on Environmental Health and Section on Dermatology: Ultraviolet radiation: a hazard to children and adolescents, Pediatrics 127(3):588–597, 2011. (Reaffirmed September 2016).
Quatrano NA, Dinulos JG: Current principles of sunscreen use in children, Curr Opin Pediatr 25:122–128, 2013.
Wu S, Cho E, Li WQ, et al: History of severe sunburn and risk of skin cancer among women and men in 2 prospective cohort studies, Am J Epidemiol 183(9):824–833, 2016.
Xu S, Kwa M, Agarwal A, et al: Sunscreen product performance and other determinants of consumer preferences, JAMA Dermatol 183(9):824–833, 2016.
Bachelez H: Interleukin 23 inhibitors for psoriasis: not just another number, Lancet 390:208–209, 2017.
Boehncke WH, Schon MP: Psoriasis, Lancet 386:983–992, 2015.
Bronckers IM, Paller AS, van Geel MJ, et al: Psoriasis in children and adolescents: diagnosis, management and comorbidities, Paediatr Drugs 17(5):373–384, 2015.
Garcia-Perez ME, Stevanovic T, Poubelle PE: New therapies under development for psoriasis treatment, Curr Opin Pediatr 25:480–487, 2013.
Landells I, Marano C, Hsu MC, et al: Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study, J Am Acad Dermatol 73:594–603, 2015.
Marrakchi S, Guigue P, Renshaw BR, et al: Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis, N Engl J Med 365:620–628, 2011.
McInnes IB, Mease PJ, Kirkham B, et al: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial, Lancet 386:1137–1146, 2015.
Paller AS, Mercy K, Kwasny MJ, et al: Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study, JAMA Dermatol 149(2):166–176, 2013.
Paller AS, Siegfried EC, Langley RG, et al: Etanercept treatment for children and adolescents with plaque psoriasis, N Engl J Med 358(3):241–251, 2008.
Papp K, Thaci D, Marcoux D, et al: Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomized, double-blind, phase 3 trial, Lancet 390:40–49, 2017.
Sanclemente G, Murphy R, Contreras J, et al: Anti-TNF agents for paediatric psoriasis, Cochrane Database Syst Rev (11):CD010017, 2015.
Shah KN: Diagnosis and treatment of pediatric psoriasis: current and future, Am J Clin Dermatol 14:195–213, 2013.
Silverberg NB: Update on pediatric psoriasis, Cutis 95(3):147–152, 2015.
The Medical Letter: Brodalumab (Siliq) — another IL-17A antagonist for psoriasis, Med Lett 59(1525):118–119, 2017.
Geller L, Antonov NK, Lauren CT, et al: Pityriasis lichenoides in childhood: review of clinical presentation and treatment options, Pediatr Dermatol 32(5):579–592, 2015.
Maranda El, Smith M, Nguyen AH, et al: Phototherapy for pityriasis lichenoides in pediatric population: a review of the published literature, Am J Clin Dermatol 17(6):583–591, 2016.
Browning JC: An update on pityriasis rosea and other similar childhood exanthems, Curr Opin Pediatr 21:481–485, 2009.
Klein A, Landthaler M, Karrer S: Pityriasis rubra pilaris: a review of diagnosis and treatment, Am J Clin Dermatol 11:157–170, 2010.
Takagi A, Kamijo M, Ikeda S: Darier disease, J Dermatol 43(3):275–279, 2016.
Payette MJ, Weston G, Humphrey S, et al: Lichen planus and other lichenoid dermatoses: kids are not just little people, Clin Dermatol 33(6):631–643, 2015.
Payette MJ, Weston G, Humphrey S, et al: Lichen planus and other lichenoid dermatoses: kids are not just little people, Clin Dermatol 33(6):631–643, 2015.
Atzmony L, Reiter O, Hodak E, et al: Treatments for cutaneous lichen planus: a systematic review and meta-analysis, Am J Clin Dermatol 17(1):11–22, 2016.
Payette MJ, Weston G, Humphrey S, et al: Lichen planus and other lichenoid dermatoses: kids are not just little people, Clin Dermatol 33(6):631–643, 2015.
Kanitakis J: Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features, Eur J Dermatol 24(5):533–544, 2014.
Brandt O, Abeck D, Gianotti R, et al: Gianotti-Crosti syndrome, J Am Acad Dermatol 54:136–145, 2006.
Kutlubay Z, Engin B, Bairamov O, Tuzun Y: Acanthosis nigricans: a fold (intertriginous) dermatosis, Clin Dermatol 33(4):466–470, 2015.
Dyer JA, Spraker M, Williams M: Care of the newborn with ichthyosis, Dermatol Ther 26(1):1–15, 2013.
Ellis E, Fischer G: Prepubertal-onset vulvar lichen sclerosus: the importance of maintenance therapy in long-term outcomes, Pediatr Dermatol 32(4):461–476,2015.
Glick JB, Craiglow BG, Choate KA, et al: Improved management of harlequin ichthyosis with advances in neonatal intensive care, Pediatrics 139(1):e20161003, 2017.
Hellstrom M, Bygum A, Gnemo A, et al: Spectrum of autosomal recessive congenital ichthyosis in Scandinavia: clinical characteristics and novel recurrent mutations in 132 patients, Acta Derm Venereol 96:932–937, 2016.
Hernandez-Martin A, Aranegui B, Martin-Santiago A, et al: A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris, J Am Acad Dermatol 69(4):544–549, 2013.
Hernandez-Martin A, Gonzalez-Sarmiento R: Recent advances in congenital ichthyoses, Curr Opin Pediatr 27:473–479, 2015.
Lai-Cheong JE, Elias PM, Paller AS: Pathogenesis-based therapies in ichthyoses, Dermatol Ther 26(1):46–54, 2013.
McLean WHI, Irvine AD: Disorders of keratinization: from rare to common genetic diseases of skin and other epithelial tissues, Ulster Med J 76(2):72–82, 2007.
Oji V, Tadini G, Akiyama M, et al: Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009, J Am Acad Dermatol 63(4):607–641, 2010.
Rajopat S, Moss C, Mellerio J, et al: Harlequin ichthyosis: a review of clinical and molecular findings in 45 cases, Arch Dermatol 147:681–686, 2011.
Sandilands A, Sutherland C, Irvine AD, et al: Filaggrin in the frontline: role in skin barrier function and disease, J Cell Sci 122(Pt 9):1285–1294, 2009.
Sethuraman G, Marwaha RK, Challa A, et al: Vitamin D: a new promising therapy for congenital ichthyosis, Pediatrics 137(1):e20151313, 2016.
Thyssen JP, Godoy-Gijon E, Elias PM: Ichthyosis vulgaris: the filaggrin mutation disease, Br J Dermatol 168(6):1155–1166, 2013.
Castells M, Metcalfe DD, Escribano L: Diagnosis and treatment of cutaneous mastocytosis in children, Am J Clin Dermatol 12:259–270, 2011.
Castori M, Camerota F, Celletti C, et al: Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients, Am J Med Genet A 152A:556–564, 2010.
Christen-Zaech S, Hakim MD, Afsar FS, et al: Pediatric morphea (localized scleroderma): review of 136 patients, J Am Acad Dermatol 59:385–396, 2008.
De Paepe A, Malfait F: The Ehlers-Danlos syndrome, a disorder with many faces, Clin Genet 82:1–11, 2012.
De Wandele I, Calders P, Peersman W, et al: Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDS types, fibromyalgia, and healthy controls, Semin Arthritis Rheum 44(3):353–361, 2014.
De Wandele I, Rombaut L, Leybaert L, et al: Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome, Semin Arthritis Rheum 44:93–100, 2014.
De Wandele I, Rombaut L, Malfait F, et al: Clinical heterogeneity in patients with the hypermobility type of Ehlers-Danlos syndrome, Res Dev Disabil 34:873–881, 2013.
Hakim A, Grahame R: Joint hypermobility, Best Pract Res Clin Rheumatol 17:989–1004, 2003.
Gotlib J, Kluin-Nelemans HC, George TI, et al: Efficacy and safety of midostaurin in advanced systemic mastocytosis, N Engl J Med 374(26):2530–2540, 2016.
Heinze A, Kuemmet TJ, Chiu YE, et al: Longitudinal study of pediatric urticaria pigmentosa, Pediatr Dermatol 34(2):144–149, 2017.
Ko JH, Shih YC, Huang YH, et al: Pseudoxanthoma elasticum, Lancet 381:585, 2013.
LaMont LE, Doyle SM: Orthopedic aspects of collagen disorders, Curr Opin Pediatr 26:79–84, 2014.
Li SC, Torok KS, Pope E, et al: Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma, Arthritis Care Res 64:1175–1185, 2012.
Li Q, Schumacher W, Jablonski D, et al: Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene, Br J Dermatol 166(5):1107–1111, 2012.
Ma HY, Hsieh WS: Disseminated skin manifestations in a neonate with incontinentia pigmenti, J Pediatr 169:510, 2011.
Martin L, Maitre F, Bonicel P, et al: Heterozygosity for a single mutation in the ABCC6 gene may closely mimic PXE, Arch Dermatol 144:301–306, 2008.
Mani C, Bruneau J, Georgin-Lavialle S, et al: Paediatric mastocytosis: a systemativ review of 1747 cases, Br J Dermatol 172:642–651, 2015.
Metcalfe DD: Mast cells and mastocytosis, Blood 112:946–956, 2008.
Milhorat TH, Bolognese PA, Nishikawa M, et al: Syndrome of occipitoatlantoaxial hypermobility, cranial settling, and Chiari malformation type 1 in patients with hereditary disorders of connective tissue, J Neurosurg Spine 7:601–609, 2007.
Morren MA, Hoppe A, Renard M, et al: Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis, J Pediatr 162:205–207, 2013.
Ong KT, Perdu J, De Backer J, et al: Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blind-endpoints trial, Lancet 376:1476–1484, 2010.
Oyama N, Chan I, Neill SM, et al: Autoantibodies to extracellular matrix protein 1 in lichen sclerosus, Lancet 362:118–123, 2003.
Parapia LA, Jackson C: Ehlers-Danlos syndrome — a historical review, Br J Haematol 141:32–35, 2008.
Schoepe S, Schake H, May E, et al: Glucocorticoid therapy-induced skin atrophy, Exp Dermatol 15:406–420, 2006.
Theoharides TC, Valent P, Akin C: Mast cells, mastocytosis, and related disorders, N Engl J Med 373(2):163–172, 2015.
Torrelo A, Alvarez-Twose I, Escribano L: Childhood mastocytosis, Curr Opin Pediatr 24:480–486, 2012.
Valent P, Akin C, Escribano L, et al: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria, Eu J Clin Invest 37:435–453, 2007.
Vearrier D, Buka RL, Roberts B, et al: What is the standard of care in the evaluation of elastosis perforans serpiginosa? A survey of pediatric dermatologists, Pediatr Dermatol 23:219–224, 2006.
Wolfram D, Tzankov A, Pulzl P, et al: Hypertrophic scars and keloids — a review of their pathophysiology, risk factors, and therapeutic management, Dermatol Surg 35:171–181, 2009.
Yoo JY, Blum RR, Singer GK, et al: A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum, J Am Acad Dermatol 65:341–348, 2011.
Hamilton MJ, Hornick JL, Akin C, et al: Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations, J Allergy Clin Immunol 128:147–152, 2011.
Lyons JJ, Yu X, Hughes JD, et al: Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number, Nat Genet 48(12):1564–1569, 2016.
Molderings GJ, Brettner S, Homann J, Afrin LB: Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options, J Hematol Oncol 4:10, 2011.
Theoharides TC, Valent P, Akin C: Mast cells, mastocytosis, and related disorders, N Engl J Med 373:163–172, 2015.
Beckers AB, Keszthelyi D, Fikree A, et al: Gastrointestinal disorders in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type: a review for the gastroenterologist, Neurogastroenterol Motil 2017. PMID: 28086259.
Borck G, Beighton P, Wilhelm C, et al: Arterial rupture in classic Ehlers-Danlos syndrome with COL5a1 mutation, Am J Med Genet A 152A:2090–2093, 2010. PMID: 20635400.
Byers PH, Murray ML: Ehlers-Danlos syndrome: a showcase of conditions that lead to understanding matrix biology, Matrix Biol 33:10–15, 2014. PMID: 23920413.
Castori M: Ehlers-Danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations, ISRN Dermatol 2012. Article ID 751768.
Castori M, Morlino S, Ghibellini G, et al: Connective tissue, Ehlers-Danlos syndrome(s), and head and cervical pain, Am J Med Genet C Semin Med Genet 169C:84–96, 2015.
Castori M, Tinkle B, Levy H, et al: A framework for the classification of joint hypermobility and related conditions, Am J Med Genet C Semin Med Genet 2017. PMID: 28145606.
Celletti C, Camerota F, Castori M, et al: Orthostatic intolerance and postural orthostatic tachycardia syndrome in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type: neurovegetative dysregulation or autonomic failure?, Biomed Res Int 9161865, 2017. PMID: 28286774.
De Wandele I, Calders P, Peersman W, et al: Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDS types, fibromyalgia, and healthy controls, Semin Arthritis Rheum 44(3):353–361, 2014.
Malfait F, Francomano C, Byers P, et al: The 2017 international classification of the Ehlers-Danlos syndromes, Am J Med Genet C Semin Med Genet 175C:8–26, 2017.
Milhorat TH, Bolognese PA, Nishikawa M, et al: Syndrome of occipitoatlantoaxial hypermobility, cranial settling, and chiari malformation type I in patients with hereditary disorders of connective tissue, J Neurosurg Spine 7:601–609, 2007.
Murphy-Ryan M, Psychogios A, Lindor NM: Hereditary disorders of connective tissue: a guide to the emerging differential diagnosis, Genet Med 12(6):344–354, 2010. PMID: 20467323.
O'Connell M, Burrows NP, van Vlijmen-Willems MJJ, et al: Tenascin-X deficiency and Ehlers-Danlos syndrome: a case report and review of the literature, Br J Dermatol 163(6):1340–2133, 2010.
Ritelli M, Dordoni C, Ventuini M, et al: Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations, Orphanet J Rare Dis 8:58, 2013.
Smits-Engelsman B, Klerks M, Kirby A: Beighton score: a valid measure for generalized hypermobility in children, J Pediatr 158:119–123, 2011. PMID: 20850761.
Sobey G: Ehlers-Danlos syndrome: how to diagnose and when to perform genetic tests, Arch Dis Child 100:57–61, 2015.
Symoens S, Syx D, Malfait F, et al: Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria, Hum Mutat 33(11):1485–1493, 2012.
Zeitoun JD, Lefevre JH, de Parades V, et al: Functional digestive symptoms and quality of life in patients with Ehlers-Danlos syndromes: results of a national cohort study on 134 patients, PLoS ONE 8(11):e80321, 2013.
Centers for Disease Control and Prevention: Outbreak of erythema nodosum of unknown cause — new Mexico, November 2007-January 2008, MMWR Morb Mortal Wkly Rep 58:1347–1351, 2009.
Lombardi G, Cabana R, Bollani L, et al: Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report, Eur J Pediatr 168:625–627, 2009.
Narvaez J, Bianchi MM, Santo P, et al: Pancreatitis, panniculitis and polyarthritis, Semin Arthritis Rheum 47:1814–1819, 2008.
Oza V, Treat J, Cook N, et al: Subcutaneous fat necrosis as a complication of whole-body cooling for birth asphyxia, Arch Dermatol 146(8):882–885, 2010.
Quesada-Cortes A, Campos-Munoz L, Daiz-Diaz RM, et al: Cold panniculitis, Dermatol Clin 26:458–459, 2008.
Simon TD, Soep J, Hollister JR: Pernio in pediatrics, Pediatrics 116:e472-e475, 2005.
Strohm B, Hobson A, Brocklehurst P, et al: Subcutaneous fat necrosis after moderate therapeutic hypothermia in neonates, Pediatrics 128:e450-e452, 2011.
Tzvi-Behr S, Megged O, Schlesinger Y, et al: Subcutaneous fat necrosis, J Pediatr 163:300, 2013.
Weingartner JS, Zedek DC, Burkhart CN, et al: Lupus erythematosus panniculitis in children: report of three cases and review of previously reported cases, Pediatr Dermatol 29:169–176, 2012.
Woods AG, Cederholm CK: Subcutaneous fat necrosis and whole-body cooling therapy for neonatal encephalopathy, Adv Neonatal Care 12(6):345–348, 2012.
Zeb A, Darmstadt GL: Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnosis and management, J Perinatol 28:453–460, 2008.
Garg A, Agarwal AK: Lipodystrophies: disorders of adipose tissue biology, Biochim Biophys Acta 1791:507–513, 2009.
Garg A: Lipodystrophies: genetic and acquired body fat disorders, J Clin Endocrinol Metab 96:3313–3325, 2011.
Milan G, Murano I, Costa S, et al: Lipoatrophy induced by subcutaneous insulin infusion: ultrastructural analysis and gene expression profiling, J Clin Endocrinol Metab 95:3126–3132, 2010.
Pope E, Janson A, Khambalia A, et al: Childhood acquired lipodystrophy: a retrospective study, J Am Acad Dermatol 55:947–950, 2006.
Vantyghem MC, Balavoine AS, Douillard C, et al: How to diagnose a lipodystrophy syndrome, Ann Endocrinol (Paris) 73:170–189, 2012.
Benson RA, Palin R, Holt PJE, et al: Diagnosis and management of hyperhidrosis, BMJ 347:28–31, 2013.
Collier F, Smith RC, Morton CA: Diagnosis and management of hidradenitis suppurativa, BMJ 346:f2121, 2013.
De Campos JR, Hashmonai M, Licht PB, et al: Treatment options for primary hyperhidrosis, Am J Clin Dermatol 13(2):139, 2012.
Egeberg A, Gislason GH, Hansen PR: Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa, JAMA Dermatol 152(4):429–434, 2016.
Kimball AB, et al: Two phase 3 trials of adalimumab for hidradenitis suppurativa, N Engl J Med 375(5):422–434, 2016.
Perera E, Sinclair R: Hyperhidrosis and bromhidrosis — a guide to assessment and management, Aust Fam Physician 42(5):266–269, 2013.
Wolosker N, Teivelis MP, Krutman M, et al: Long-term efficacy of oxybutynin for palmar and plantar hyperhidrosis in children younger than 14 years, Pediatr Dermatol 32(5):663–667, 2014.
Woodruff CM, Charlie AM, Leslie KS: Hidradenitis suppurativa: a guide for the practicing physician, Mayo Clin Proc 90(12):1679–1693, 2015.
Castelo-Soccio L: Diagnosis and management of hair loss in children, Curr Opin Pediatr 28:483–489, 2016.
Damsky W, King B: JAK inhibitors in dermatology: the promise of a new drug class, J Am Acad Dermatol 2017. pii: S0190-9622(16)31188-4.
Gilhar A, Etzioni A, Paus R: Alopecia areata, N Engl J Med 366:1515–1524, 2012.
Goren A, Shapiro J, Sinclair R, et al: a1-AR agonist induced piloerection protects against the development of traction alopecia, Dermatol Ther 29(3):160–163, 2016.
Harries MJ, Sun J, Paus R, et al: Management of alopecia areata, BMJ 341:242–246, 2010.
Huang KP, Mullangi S, Guo Y, et al: Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States, JAMA Dermatol 149(7):789–794, 2013.
Mirmirani P, Huang KP, Price VH: A practical, algorithmic approach to diagnosing hair shaft disorders, Int J Dermatol 50(1):1–12, 2011.
Orgaz-Molina J, Fernandez-Pugnaire MA, Giron-Prieto M: A scalp disorder: dermatoscopy as a useful diagnostic tool, J Pediatr 162:876–877, 2013.
Van Zuuren EJ, Fedorowicz Z: Interventions for hirsutism, JAMA 314(17):1863–1864, 2015.
Chernoff K, Scher R: Nail disorders: kids are not just little people, Clin Dermatol 34:736–774, 2016.
Eekhof JA, Van Wijk B, Knuistingh Neven A, et al: Interventions for ingrowing toenails, Cochrane Database Syst Rev (4):CD001541, 2012.
Eichenfield L, Friedlander S: Pediatric onychomycosis: the emerging role of topical therapy, J Drugs Dermatol 16(2):105–109, 2017.
Eisman S, Sinclair R: Fungal nail infection: diagnosis and management, BMJ 348:g1800, 2014.
Elewski BE, Rich P, Pollak R, et al: Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies, J Am Acad Dermatol 68:600–608, 2013.
Fawcett RS, Linford S, Stulberg DL: Nail abnormalities: clues to systemic disease, Am Fam Physician 69:1417–1424, 2004.
Gregoriou S, Agryriou G, Larios G, et al: Nail disorders and systemic disease: what the nails tell us, J Fam Pract 57:509–514, 2008.
Howard SR, Siegfried EC: A case of leukonychia, J Pediatr 163:914–915, 2013.
Jenec GB, Kollerup G, Jensen LB, Mogensen S: Nail abnormalities in nondermatologic patients: prevalence and possible role as diagnostic aids, J Am Acad Dermatol 32:977–981, 1995.
Le Corre Y, Steff M, Croue A, et al: Hereditary leukonychia totalis, acanthosis-nigticans-like lesions and hair dysplasia: a new syndrome?, Eur J Med Genetics 52:229–233, 2009.
Lomax A, Thornton J, Singh D: Toenail paronychia, Foot and Ankle Surgery 22:219–223, 2016.
The Medical Letter: Efinaconazole topical solution (jublia) for onychomycosis, Med Lett 56(1451):88–89, 2014.
The Medical Letter: Laser treatment of onychomycosis, Med Lett Drugs Ther 55:15–16, 2013.
Piraccini BM, Starace M: Nail disorders in infants and children, Curr Opin Pediatr 26:444–445, 2014.
Shah KN, Rubin AI: Nail disorders as signs of pediatric systemic disease, Curr Probl Pediatr Adolesc Health Care 42(8):204–211, 2012.
Singal A: Daulatabad d: nail tic disorders: manifestations, pathogenesis and management, Indian J Dermatol Venereol Leprol 83(1):19–26, 2017.
Tully AS, Trayes KP, Studdiford JS: Evaluation of nail abnormalities, Am Fam Physician 85(8):779–787, 2012.
Brocklehurst P, Tickle M, Glenny AM, et al: Systemic interventions for recurrent aphthous stomatitis (mouth ulcers), Cochrane Database Syst Rev (9):CD005411, 2012.
Enwonwu CO: Noma — the ulcer of extreme poverty, N Engl J Med 354(3)221–224,2006.
Gonsalves WC, Chi AC, Neville BW: Common oral lesions: part 1. Superficial mucosal lesions, Am Fam Physician 75:501–507, 2007.
Hello M, Barbarot S, Bastuji-Garin S, et al: Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis, Medicine (Baltimore) 89(3): 176–182, 2010.
Nico MM, Park JH, Lourenco SV: Mucocele in pediatric patients: analysis of 36 children, Pediatr Dermatol 25:308–311, 2008.
Pilarski R, Burt R, Kohlman W, et al: Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria, J Natl Cancer Inst 105(21):1607–1616, 2013.
Schlager E, St. Claire C, Ashack K, Khachemoune A: Black hairy tongue: predisposing factors, diagnosis, and treatment, Am J Clin Dermatol 2017. PMID 28247090.
Bangert S, Levy M, Herbert AA: Bacterial resistance and impetigo treatment trends: a review, Pediatr Dermatol 29:243–248, 2012.
Bowen AC, Tong SYC, Andrews RM, et al: Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomized, controlled, non-inferiority trial, Lancet 384:2132–2140, 2014.
Chen AE, Carroll KC, Diener-West M: Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections, Pediatrics 127(3):e573-e580, 2011.
Hartman-Adams H, Banvard C, Juckett G: Impetigo: diagnosis and treatment, Am Fam Physician 90(4):229–235, 2014.
Koning S, van der Sande R, Verhagen AP, et al: Interventions for impetigo, Cochrane Database Syst Rev (1):CD003261, 2012.
Boucher HW, Wilcox M, Talbot GH, et al: Once-weekly dalbavancin versus daily conventional therapy for skin infection, N Engl J Med 370:2169–2178, 2014.
Cardona AF, WilsonSE: Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment, Clin Infect Dis 61(Suppl 2):S69-S79, 2015.
Halilovic J, Heintz BH, Brown J: Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess, J Infect 65:128–134, 2012.
King E, Chun R, Sulman C: Pediatric cervicofacial necrotizing fasciitis, Arch Otolaryngol Head Neck Surg 138:372–375, 2012.
Malone JR, Durica SR, Thompson DM, et al: Blood cultures in the evaluation of uncomplicated skin and soft tissue infections, Pediatrics 132:454–459, 2013.
Marin JR, Dean AJ, Bilker WB, et al: Emergency ultrasound-assisted examination of skin and soft tissue infections in the pediatric emergency department, Acad Emerg Med 20:545–553, 2013.
Moran GJ, Krishnadasan A, Mower WR, et al: Effect of cephalexin plus trimethoprim-sulfamethoxazole vs. cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial, JAMA 317(20):2088–2096, 2017.
Phoenix G, Das S, Joshi M: Diagnosis and management of cellulitis, BMJ 345:e4955, 2012. Prokocimer P, De Anda C, Fang E, et al: Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections, JAMA 309:559–568, 2013.
Raff AB, Kroshinsky D: Cellulitis: a review, JAMA 316:325–337, 2016.
Stevens DL, Bisno AL, Chambers HF, et al: Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America, Clin Infect Dis 59:147–159, 2014.
The Medical Letter: Two new drugs for skin and skin structure infections, Med Lett Drugs Ther 56:73–76, 2014.
US Food and Drug Administration: FDA approves Orbactiv to treat skin infections. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm408475.htm.
Zabielinski M, McLeod MP, Aber C, et al: Trends and antibiotic susceptibility patterns of methicillin-resistant and methicillin-sensitive Staphylococcus aureus in an outpatient dermatology facility, JAMA Dermatol 149:427–432, 2013.
Braunstein I, Wanat KA, Abuabara K, et al: Antibiotic sensitivity and resistance patterns in pediatric staphylococcal scalded skin syndrome, Pediatr Dermatol 31:305–308, 2014.
Courjon J, Hubiche T, Phan A, et al: Skin findings of Staphylococcus aureus toxin-mediated infection in relation to toxin encoding genes, Pediatr Infect Dis J 32(7):727–730, 2013 Jul. doi:10.1097/INF.0b013e31828e89f5.
Handler MZ, Schwartz RA: Staphylococcal scalded skin syndrome: diagnosis and management in children and adults, J Eur Acad Dermatol Venereol 28(11):1418–1423, 2014.
Goolamali SI, Fogo A, Killian L, et al: Ecthyma gangrenosum: an important feature of pseudomonal sepsis in a previously well child, Clin Exp Dermatol 34:e180-e182, 2008.
Paller AS, Mancini AJ: Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence, ed 5, Philadelphia, 2016, WB Saunders, pp 334–359.
Vaiman M, Lazarovitch T, Heller L, et al: Ecthyma gangrenosum and ecthyma-like lesions: review article, Eur J Clin Microbiol Infect Dis 34(4):633–669, 2015.
Blaise G, Nikkels AF, Hermanns-Le T, et al: Corynebacterium-associated skin infections, Int J Dermatol 47:884–890, 2008.
Boyd AS, Ritchie C, Fenton JS: Cutaneous Erysipelothrix rhusiopathiae (erysipeloid) infection in an immunocompromised child, Pediatr Dermatol 31(2):232–235, 2014.
Bradley J, Glasser C, Patino H, et al: Daptomycin for complicated skin infections: a randomized trial, Pediatrics 139(3):e20162477, 2017.
Daum RS, Miller LG, Immergluck L, et al: A placebo-controlled trial of antibiotics for smaller skin abscesses, N Engl J Med 376(26):2545–2554, 2017.
Guidry JA, Downing C, Tyring SK: Deep fungal infections, blastcomycosis-like pyoderma, and granulomatous sexually transmitted infections, Dermatol Clin 33(3):595–607, 2015.
Holmes L, Ma C, Qiao H, et al: Trimethoprim-sulfamethoxazole therapy reduces failure and recurrence in methicillin-resistant Staphylococcus aureus skin abscesses after surgical drainage, J Pediatr 169:128–134, 2016.
Johnson MG, Stout JE: Twenty-eight cases of Mycobacterium marinum infection: retrospective case series and literature review, Infection 43(6):655–662, 2015 Dec. doi:10.1007/s15010-015-0776-8. [Epub 2015 Apr 14].
McClain SL, Bohan JG, Stevens DL: Advances in the medical management of skin and soft tissue infections, BMJ 355:i6004, 2016.
Meury SN, Erb T, Schaad UB, et al: Randomized, comparative efficacy trial of oral penicillin versus cefuroxime for perianal streptococcal dermatitis, J Pediatr 153: 799–802, 2008.
Miller LG, Daum RS, Creech CB, et al: Clindamycin versus trimethoprim-sulfamethox- azole for uncomplicated skin infections, N Engl J Med 372(12):1093–1102, 2015.
Moran GJ, Krishnadasan A, Mower WR, et al: Effect of cephalexin plus trimethoprimsulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial, JAMA 317(20):2088–2096, 2017.
Obaitan I, Dwyer R, Lipworth AD, et al: Failure of antibiotics in cellulitis trials: a systematic review and meta-analysis, Am J Emerg Med 34(8):1645–1652, 2016.
Raff AB, Kroshinsky D: Cellulitis: a review, JAMA 316(3):325–336, 2016.
Rentala M, Andrews S, Tiberio A, et al: Intravenous home infusion therapy instituted from a 24-hour clinical decision unit for patients with cellulitis, Am J Emerg Med 34(7):1273–1275, 2016.
Stevens DL, Bisno AL, Chambers HF, et al: Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America, Clin Infect Dis 59(2):e10-e52, 2014.
Talan DA, Mower WR, Krishnadasan A, et al: Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess, N Engl J Med 374(9):823–832, 2016.
Weng QY, Raff AB, Cohen JM, et al: Costs and consequences associated with misdiagnosed lower extremity cellulitis, JAMA Dermatol 153(2):141–146, 2017.
Chen X, Jiang X, Yang M, et al: Systemic antifungal therapy for tinea captitis in children, Cochrane Database Syst Rev (5):CD004685, 2016.
Elewski BE, Caceres HW, DeLeon L, et al: Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trial, J Am Acad Dermatol 59:41–54, 2008.
Friedlander SF, Chan YC, Chan YH, et al: Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy, Pediatr Dermatol 30(3): 316–322, 2013.
Grover C, Arora P, Manchanda V: Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis, Int J Dermatol 51:455–458, 2012.
Gupta AK, MacLeod MA, Foley KA, et al: Fungal skin infections, Pediatr Rev 38(1):8–22, 2017.
Gupta AK, Paquet M, Simpson F, et al: Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of the efficacy for continuous and intermittent regimens, J Eur Acad Dermatol Venereol 27(3):267–272, 2013.
Kisand K, Peterson P: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis, Curr Opin Pediatr 25:715–721, 2013.
Moriarty B, Hay R, Morris-Jones R: The diagnosis and management of tinea, BMJ 345:e4380, 2012.
Paller AS, Mancini AJ: Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence, ed 5, Philadelphia, 2016, WB Saunders, pp 402–427.
The Medical Letter: Luliconazole cream (Luzu) for tinea infections, Med Lett Drugs Ther 56:50–51, 2014.
Zampella JG, Kwatra SG, Blanck J, Cohen B: Tinea in tots: cases and literature review of oral antifungal treatment of tinea capitis in children under 2 years of age, J Pediatr 183:12–18, 2016.
Ahn CS, Hugan WW: Imiquimod in the treatment of cutaneous warts: an evidence-based review, Am J Cin Dermatol 15:387–399, 2014.
Arnold AW, Hofbauer GF: Human papillomavirus and squamous cell cancer of the skin — epidermodysplasia verruciformis-associated human papillomavirus revisited, Curr Probl Dermatol 43:49–56, 2017.
Basdag H, Rainer BM, Cohen BA: Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic setting in the Northeastern United States, Pediatr Dermatol 32(3):353–357, 2015.
Bavinck JNB, Eekhof JAH, Bruggink SC: Treatments for common and plantar warts, BMJ 342:d3119, 2011.
Bruggink SC, Eekhof JAH, Egberts PF, et al: Warts transmitted in families and schools: a prospective cohort, Pediatrics 131:928–934, 2013.
Bruggink SC, Eekhof JAH, Egberts PF, et al: Natural course of cutaneous warts among primary schoolchildren: a prospective cohort study, Ann Fam Med 11:437–444, 2013.
Butala N, Siegfried E, Weissler A: Molluscum BOTE sign: a predictor of imminent resolution, Pediatrics 131:e1650-e1653, 2013.
Cockayne S, Hewitt C, Hicks K, et al: Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): a randomized controlled trial, BMJ 342:d3271, 2011.
Gao YL, Gao XH, Qi RQ, et al: Clinical evaluation of local hyperthermia at 44oC for Mollusca contagiosa: piolt study with 21 patients, Br J Derm 176(3):809–812, 2017.
Katz KA: Dermatologists, imiquimod, and the treatment of molluscum contagiosum in children: righting wrongs, JAMA Dermatol 152(2):125–126, 2015.
Kwok CS, Gibbs S, Bennett C, et al: Topical treatments for cutaneous warts, Cochrane Database Syst Rev (9):CD001781, 2012.
Pandey S, Wilmer EN, Morrell DS: Examining the efficacy and safety of squaric acid therapy for treatment of recalcitrant warts in children, Pediatr Dermatol 32(1):85–90, 2015.
Park IU, Introcaso C, Dunne EF: Human papillomavirus and genital warts: a review of the evidence for the 2015 centers for disease control and prevention sexually transmitted disease treatment guidelines, Clin Infect Dis 61(8):s849-s855, 2015.
Ruch J, Dinulos JG: Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiosum, and warts, Curr Opin Pediatr 28:250–257, 2016.
Sterling J: Treatment of warts and molluscum: what does the evidence show?, Curr Opin Pediatr 28:490–499, 2016.
Sterling JC, Gibbs S, Haque Hussain HH, et al: British association of dermatologists' guideline for the management of cutaneous warts 2014, Br J Dermatol 171:696–712, 2014.
Van der Wouden JC, van der Sande R, Kruithof EJ, et al: Interventions for cutaneous molluscum contagiosum (review), Cochrane Database Syst Rev (5):Art. No. CD004767, 2017.
Alpern JD, Dunlop SJ, Dolan BJ, et al: Personal protection measures against mosquitoes, ticks, and other arthropods, Med Clin North Am 100(2):303–316, 2016.
Bernardeschi C, Le Cleach L, Delaunay P, et al: Bed bug infestation, BMJ 346:f138, 2013.
Hernandez RG, Cohen BA: Insect bite-induced hypersensitivity and the SCRATCH principles: a new approach to papular urticaria, Pediatrics 118:e189-e196, 2006.
Juckett G: Arthropod bites, Am Fam Physician 88(12):841–847, 2013.
The Medical Letter: Insect repellents, Med Lett Drugs Ther 54:75–76, 2012.
Boralevi F, Diallo A, Miquel J, et al: Clinical phenotype of scabies by age, Pediatrics 133:e910-e916, 2014.
Currie BJ, McCarthy JS: Permethrin and ivermectin for scabies, N Engl J Med 362:717–725, 2010.
Goldust M, Rezaee E: Hemayat s. Treatment of scabies: comparison of permethrin 5% versus ivermectin, J Dermatol 39:545–547, 2012.
Guergue Diaz de Cerio O, del Rosario Gonzales Hermosa M, Ballestero D^ez M: Bullous scabies in a 5-year-old-child, J Pediatr 179:270, 2016.
Mohebbipour A, Saleh P, Goldust M, et al: Comparison of oral ivermectin vs. lindane lotion 1% for the treatment of scabies, Clin Exp Dermatol 38:719–723, 2013.
Mounsey KE, McCarthy KS: Treatment and control of scables, Curr Opin Infect Dis 26(2):133–139, 2013.
Paller AS, Mancini AJ, Hurwitz S: Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence, ed 4, Philadelphia, 2011, Elsevier, pp 416–435.
Panahi Y, Poursaleh Z, Goldust M: The efficacy of topical and oral ivermectin in the treatment of human scabies, Ann Parasitol 61(1):11–16, 2015.
Romani L, Whitfeld MJ, Koroivueta J, et al: Mass drug administration for scabies control in a population with endemic disease, N Engl J Med 373(24):2305–2313, 2015.
Strong M, Johnstone PW: Interventions for treating scabies, Cochrane Database Syst Rev (18):CD000320, 2007.
Thompson MJ, Engelman D, Gholam K, et al: Systematic review of the diagnosis of scabies in therapeutic trials, Clin Exp Dermatol 42(5):481–487, 2017. doi:10.1111/ ced.13152. [Epub 2017 May 29].
Ameen M, Arenas R, Villanueva-Reyes J, et al: Oral ivermectin for treatment of pediculosis capitis, Pediatr Infect Dis J 29(11):991–993, 2010.
Burgess IF, Brunton ER, Burgess NA: Single application of 4% dimethicone liquid gel versus two applications of 1% permethrin creme rinse for treatment of head louse infestation: a randomised controlled trial, BMC Dermatol 13(5):1–7, 2013.
Chosidow O, Giraudeau B, Cottrell J, et al: Oral ivermectin versus malathion lotion for difficult-to-treat head lice, N Engl J Med 362(10):896–904, 2010.
Deeks LS, Naunton M, Currie MJ, et al: Topical ivermectin 0.5% lotion for treatment of head lice, Ann Pharmacother 47(9):1161–1167, 2013.
Devore CD, Schutze GE, et al: Head lice, Pediatrics 135(5):e1355-e1365, 2015.
Currie BJ, McCarthy JS: Permethrin and ivermectin for scabies, N Engl J Med 362(8):717–724, 2010.
Frankowski BL, Bocchini JA Jr: Council on school health and committee on infectious diseases: clinical report: head lice, Pediatrics 126:392–403, 2010.
Friedmeier H: Treatment of pediculosis capitis: a critical appraisal of the current literature, Am J Clin Dermatol 15(5):401–412, 2014.
Hazan L, Berg JE, Bowman JP, et al: Pharmacokinetics and safety of 0.5% ivermectin lotion for head louse infestations, Pediatr Dermatol 30:323–328, 2013.
Lebwohl M, Clark L, Levitt J: Therapy for head lice based on life cycle, resistance, and safety considerations, Pediatrics 119:965–974, 2007.
The Medical Letter: Drugs for head lice, Med Lett Drugs Ther 58(1508):150–152, 2016.
Meinking TL, Villar ME, Vicaria M, et al: The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis), Pediatr Dermatol 27(1):19–24, 2010.
Ameen M, Arenas R, Villanueva-Reyes J, et al: Oral ivermectin for treatment of pediculosis capitis, Pediatr Infect Dis J 29(11):991–993, 2010.
Burgess IF, Brunton ER, Burgess NA: Single application of 4% dimethicone liquid gel versus two applications of 1% permethrin cr?me rinse for treatment of head louse infestation: a randomised controlled trial, BMC Dermatol 13(5):1–7, 2013.
Chosidow O, Giraudeau B, Cottrell J, et al: Oral ivermectin versus malathion lotion for difficult-to-treat head lice, N Engl J Med 362(10):896–904, 2010.
Deeks LS, Naunton M, Currie MJ, et al: Topical ivermectin 0.5% lotion for treatment of head lice, Ann Pharmacother 47(9):1161–1167, 2013.
Devore CD, Schutze GE, et al: Head lice, Pediatrics 135(5):e1355–e1365, 2015.
Currie BJ, McCarthy JS: Permethrin and ivermectin for scabies, N Engl J Med 362(8):717–724, 2010.
Frankowski BL, Bocchini JA Jr: Council on school health and committee on infectious diseases: clinical report: head lice, Pediatrics 126:392–403, 2010.
Friedmeier H: Treatment of pediculosis capitis: a critical appraisal of the current literature, Am J Clin Dermatol 15(5):401–412, 2014.
Hazan L, Berg JE, Bowman JP, et al: Pharmacokinetics and safety of 0.5% ivermectin lotion for head louse infestations, Pediatr Dermatol 30:323–328, 2013.
Lebwohl M, Clark L, Levitt J: Therapy for head lice based on life cycle, resistance, and safety considerations, Pediatrics 119:965–974, 2007.
The Medical Letter: Drugs for head lice, Med Lett Drugs Ther 58(1508):150–152, 2016.
Meinking TL, Villar ME, Vicaria M, et al: The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis), Pediatr Dermatol 27(1):19–24, 2010.
Asai Y, Baibergenova A, Dutil M, et al: Management of acne: Canadian clinical practice guideline, CMAJ 188(2):118–126, 2016.
Barbaric J, Abbott R, Posadzki P, et al: Light therapies for acne (review). Cochrane Database System Rev Issue 9, Art. No. CD007917, 2016.
Blasiak RC, Starney BS, Burkhart CN, et al: High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris, JAMA Dermatol 149:1392–1398, 2013.
Carneiro S, Sampaio-Barros PD: SAPHO syndrome, Rheum Dis Clin North Am 29:401–418, 2013.
Eichenfield LF, Krakowski AC, Piggott C, et al: Evidence-based recommendations for the diagnosis and treatment of acne, Pediatrics 131(Suppl 3):S163-S186, 2013.
Greywal T, Zaenglein AL, Baldwin HE, et al: Evidence-based recommendations for the management of acne fulminans and its variants, J Am Acad Dermatol 77(1): 109–117, 2017.
Hansen TJ, Lucking S, Miller JJ, et al: Standardized laboratory monitoring with use of isotretinoin in acne, J Am Acad Dermatol 72(2):323–328, 2016.
Kim W, Mancini AJ: Acne in childhood: an update, Pediatr Ann 42(10):418–427, 2013.
Krakowski AC, Stendardo S, Eichenfield LF: Practical considerations in acne treatment and the clinical impact of topical combination therapy, Pediatr Dermatol 25:S1-S14, 2008.
Lee YH, Scharnitz TP, Muscat J, et al: Laboratory monitoring during isotretinoin therapy for acne — a systematic review and meta-analysis, JAMA Dermatol 152(1):35–44, 2016.
Magin P, Sullivan J: Suicide attempts in people taking isotretinoin for acne, BMJ 341:c5866, 2010.
Zaenglein AL, Shamban A, Webster G, et al: A phase IV open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl preparation in patients with moderate to severe acne vulgaris, J Drugs Dermatol 12(6):619–625, 2013.
Zaenglein AL, Pathy AL, Scholsser BJ, et al: Guidelines of care for the management of acne vulgaris, J Am Acad Dermatol 74(5):945–973, 2016.
Campbell LB, Kreicher KL, Gittleman HR, et al: Melanoma incidence in children and adolescents: decreasing trends in the United States, J Pediatr 166(6):1505–1513, 2015.
Jaju PD, Ransohoff KJ, Tang JY, et al: Familial skin cancer syndromes: increased risk of nonmelanotic skin cancers and extracutaneous tumors, J Am Acad Dermatol 74(3):437–451, 2016.
John AM, Schwartz RA: Basal cell naevus syndrome: an update on genetics and treatment, Br J Dermatol 174(1):68–76, 2016.
Kang HC, Baek ST, Song S, Gleeson JG: Clinical and genetic aspects of the segmental overgrowth spectrum due to somatic mutations in PIK3CA, J Pediatr 167(5):957–962, 2015.
Geeraert P, Williams JS, Brownell I: Targeting the hedgehog pathway to treat basal cell carcinoma, J Drugs Dermatol 12(5):519–523, 2013.
Kang H, Baek ST, Song S, et al: Clinical and genetic aspects of the segmental overgrowth spectrum due to somatic mutations in PIK3CA, J Pediatr 167(5):957–962, 2015.
Khosravi H, Schmidt B, Huang JT: Characteristics and outcomes of nonmelanoma skin cancer (NMSC) in children and young adults, J Am Acad Dermatol 73(5):785–790, 2015.
Luks VL, Kamitaki N, Vivero MP, et al: Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA, J Pediatr 166:1048–1054, 2015.
Mirzaa C, Timms AE, Conti V, et al: PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution, JCI Insight 1(9):e87623, 2016.
Schmidt LS, Linehan WM: Molecular genetics and clinical features of Birt-Hogg-Dube syndrome, Nat Rev Urol 12(10):558–569, 2015.
Alvares M, Kao L, Mittal V, et al: Misdiagnosed food allergy resulting in severe malnutrition in an infant, Pediatrics 132(1):e229-e332, 2013.
Gehrig KA, Dinulos JGH: Acrodermatitis due to nutritional deficiency, Curr Opin Pediatr 22:107–112, 2010.
Golriz F, Donnelly LF, Devaraj S, Krishnamurthy R: Modern American scurvy: experience with vitamin C deficiency at a large children's hospital, Pediatr Radiol 47(2):214–220, 2017.
Hammersen J, Has C, Galiano M, et al: Sustained need for high-dose zinc supplementation in children with acrodermatitis enteropathica, Clin Pediatr (Phila) 2017. doi:10.1177/0009922816685820.
Jen M, Yan AC: Syndromes associated with nutritional deficiency and excess, Clin Dermatol 28(6):669–685, 2010.
Lakdawala N, Grant-Kels J: Acrodermatitis enteropathica and other nutritional diseases of the folds (intertriginous areas), Clin Dermatol 33:414–419, 2015.
